Clovis Oncology Stock Book Value Per Share
| CLVSDelisted Stock | USD 0.09 0.02 24.00% |
Clovis Oncology fundamentals help investors to digest information that contributes to Clovis Oncology's financial success or failures. It also enables traders to predict the movement of Clovis Stock. The fundamental analysis module provides a way to measure Clovis Oncology's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Clovis Oncology stock.
Clovis |
Clovis Oncology Company Book Value Per Share Analysis
Clovis Oncology's Book Value per Share (B/S) can be calculated by subtracting liabilities from assets, and then dividing it by the total number of currently outstanding shares. It indicates the level of safety associated with each common share after removing the effects of liabilities. In other words, a shareholder can use this ratio to see how much he or she can sell the stake in the company in the event of a liquidation.
More About Book Value Per Share | All Equity Analysis
Book Value per Share | = | Common EquityAverage Shares |
Current Clovis Oncology Book Value Per Share | (2.89) X |
Most of Clovis Oncology's fundamental indicators, such as Book Value Per Share, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Clovis Oncology is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
The naive approach to look at Book Value per Share is to compare it to current stock price. If Book Value per Share is higher than the currently traded stock price, the company can be considered undervalued. However, investors must be aware that conventional calculation of Book Value does not include intangible assets such as goodwill, intellectual property, trademarks or brands and may not be an appropriate measure for many firms.
CompetitionIn accordance with the recently published financial statements, the book value per share of Clovis Oncology is about -2.886 times. This is 69.76% higher than that of the Biotechnology sector and 98.84% lower than that of the Health Care industry. The book value per share for all United States stocks is 100.15% higher than that of the company.
Clovis Book Value Per Share Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Clovis Oncology's direct or indirect competition against its Book Value Per Share to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Clovis Oncology could also be used in its relative valuation, which is a method of valuing Clovis Oncology by comparing valuation metrics of similar companies.Clovis Oncology is currently under evaluation in book value per share category among its peers.
Clovis Fundamentals
| Return On Asset | -0.3 | |||
| Profit Margin | (1.89) % | |||
| Operating Margin | (1.55) % | |||
| Current Valuation | 651.32 M | |||
| Shares Outstanding | 144.96 M | |||
| Shares Owned By Insiders | 1.43 % | |||
| Shares Owned By Institutions | 25.89 % | |||
| Number Of Shares Shorted | 28.49 M | |||
| Price To Earning | (8.65) X | |||
| Price To Sales | 0.11 X | |||
| Revenue | 148.76 M | |||
| Gross Profit | 115.3 M | |||
| EBITDA | (224.76 M) | |||
| Net Income | (264.52 M) | |||
| Cash And Equivalents | 94.58 M | |||
| Cash Per Share | 0.65 X | |||
| Total Debt | 436.77 M | |||
| Debt To Equity | 810.00 % | |||
| Current Ratio | 1.17 X | |||
| Book Value Per Share | (2.89) X | |||
| Cash Flow From Operations | (196.06 M) | |||
| Short Ratio | 4.63 X | |||
| Earnings Per Share | (2.08) X | |||
| Price To Earnings To Growth | 0.13 X | |||
| Target Price | 2.0 | |||
| Number Of Employees | 413 | |||
| Beta | 0.22 | |||
| Market Capitalization | 11.77 M | |||
| Total Asset | 472.83 M | |||
| Retained Earnings | (2.3 B) | |||
| Working Capital | 464.12 M | |||
| Current Asset | 539.7 M | |||
| Current Liabilities | 75.58 M | |||
| Z Score | -5.6 | |||
| Net Asset | 472.83 M |
About Clovis Oncology Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Clovis Oncology's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Clovis Oncology using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Clovis Oncology based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. You can also try the Watchlist Optimization module to optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm.
Other Consideration for investing in Clovis Stock
If you are still planning to invest in Clovis Oncology check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Clovis Oncology's history and understand the potential risks before investing.
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins |